SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending following a strong earnings report, with many analysts raising their price targets and the community buzzing about the company's dominance in AI. Discussions revolve around whether the AI sector is in a bubble, the impact of potential US-Saudi investment, and the sustainability of Nvidia's growth.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart's trending status is fueled by strong earnings results and an increased full-year outlook, leading to community excitement. The company's decision to transfer its stock exchange listing to Nasdaq is also a hot topic. Community members are closely watching how these factors will influence the stock's performance.

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings is trending due to community excitement around a potential short squeeze, with claims of high short interest and a low float driving significant volatility. Discussions center on holding above key price levels and pushing for substantial gains, drawing parallels to previous meme stock rallies. The community is actively encouraging each other to hold firm, anticipating a major move.

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Exact Sciences Corp.

Exact Sciences (EXAS) is trending amid news of a potential acquisition by Abbott (ABT) at $105 per share, which would give ABT leadership in the cancer screening market with Cologuard. The community is buzzing about the details of the deal and potential bidding wars, while also recognizing long-term holders who have profited from the stock's performance. Some caution that the deal isn't final, highlighting the potential for a hard retrace if talks collapse.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending as investors weigh potential takeover bids against concerns about shipping rates and recent earnings. Community discussions focus on the possibility of a buyout, with some speculating on potential offer prices and the board's intentions, while others express concern over the stock's recent performance and the impact of global trade dynamics.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab (RKLB) is trending due to recent back-to-back Electron launches, showcasing the company's ability to scale operations. The community is focused on the launch live streams and what this increased launch cadence signals for future growth. Investors are optimistic, citing Rocket Lab's strong YTD performance and analyst price targets, positioning RKLB as a key player in the responsive space sector.

Bath & Body Works, Inc. is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. The company was founded by Leslie Herbert Wexner in 1963 and is headquartered in Columbus, OH.

Bath & Body Works Inc

BBWI is trending as investors assess its potential ahead of earnings, especially given recent analyst ratings and a new share repurchase program. The community is weighing mixed signals, from new product launches and a push into college campuses, against concerns around consumer spending and sector performance. Some see the stock as undervalued with a strong potential for a holiday season boost, while others express concerns about declining sales and increasing put options.

PACS Group, Inc. is a holding company, which engages in the provision of post-acute healthcare facilities, professionals, and ancillary services. It provides senior care, assisted living, and independent living options in some of the communities. The company was founded by Jason Murray and Mark Hancock in 2013 and is headquartered in Farmington, UT.

PACS Group Inc.

PACS Group is trending due to a strong Q3 update and positive after-hours movement, with investors focusing on census/occupancy trends and balance sheet flexibility. The community is actively discussing the company's revenue guidance relative to competitors and potential upside based on analyst targets and healthcare expansion. Overall, there is buzz around steady inflow, healthcare expansion buzz, and the company's regained SEC compliance.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending due to a combination of strong Q1 earnings results and the recent acquisition of Chronosphere, though some investors are questioning the price tag. Community discussions revolve around the company's growth potential in cybersecurity, particularly its AI-driven platform, and analyst upgrades with higher price targets. Despite positive sentiment, the stock experienced a slight dip, sparking debates about market manipulation and future performance relative to competitors like NVDA.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

ABT is trending following news of its acquisition of Exact Sciences ($EXAS) for $21 billion, a move that would significantly expand its cancer screening and diagnostics portfolio. Community discussions revolve around the potential benefits for Abbott in the oncology segment and the valuation of Exact Sciences, with some suggesting a possible bidding war. The acquisition adds a new growth vertical, positioning Abbott as a leader in the fast-growing U.S. cancer screening and precision oncology diagnostics markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Novartis raised peak sales targets for Kisqali and Scemblix, adding to its roster of multi-billion-dollar oncology drugs.</li><li>The company extended its mid-term growth outlook through 2030, supported by a deep pipeline and upcoming clinical readouts.</li><li>The raised targets come amid U.S. expansion plans and continued job cuts.</li></ul><p>Novartis’ U.S.-listed shares traded 0.1% lower pre-market on Thursday, even after the company raised long-term sales expectations for two of its key oncology medicines and rolled forward its mid-term growth outlook through 2030.&nbsp;</p><h2 class="st-heading-2"><strong>Stronger Peak Sales Outlook For Kisqali And Scemblix</strong></h2><p>The company boosted its top sales estimate for breast-cancer drug Kisqali to more than $10 billion from more than $8 billion. Leukemia treatment Scemblix could generate over $4 billion, it said, compared with its previous estimate of more than $3 billion. With those increases, the Swiss company now has eight marketed drugs that it believes can each generate between $3 billion and more than $10 billion at peak, a group that also includes Cosentyx, Pluvicto, Kesimpta, Leqvio, Fabhalta and Rhapsido.</p><p>The raised targets highlight the company’s push to rely more heavily on oncology growth drivers as older blockbusters, such as Entresto, face rising generic pressure.</p><h2 class="st-heading-2"><strong>Mid-Term Sales Growth Extended To 2030</strong></h2><p>Novartis updated its mid-term guidance to 5%-6% annual sales growth at constant currency from 2025 to 2030, extending its prior 2024–2029 outlook.&nbsp;</p><p>The company said more than 15 potentially submission-enabling readouts are expected in the next two years, part of a broader pipeline of over 30 potential high-value medicines, more than 10 of which were licensed or acquired within the past two years.</p><p>The company reported a 41.2% core operating margin for the first nine months of 2025 and expects margins to stay above 40% by 2029 after absorbing dilution from its planned acquisition of Avidity Biosciences.</p><h2 class="st-heading-2"><strong>US Expansion And Job Cuts</strong></h2><p>The guidance comes after Novartis revealed plans for a major expansion of U.S. operations, with the addition of a new North Carolina manufacturing facility that’s part of a larger $23 billion investment plan for the company. That site is projected to create 700 new jobs as part of its efforts to build advanced manufacturing capabilities across various therapeutic areas.</p><p>The pharma giant is also continuing to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/big-pharma-layoff-wave-extends-into-next-year-unh-merck-bms-novartis-file-new-warn-notices/cLPA3QMRE9a">cut its workforce in New Jersey</a>, where it plans to lay off 60 workers by the middle of next year. The job cuts follow a reduction of 426 people earlier this year, as well as other reductions in 2024 and 2022 as part of the company’s cost-efficiency efforts.</p><h2 class="st-heading-2"><strong>Stocktwits Mood Leans Bearish</strong></h2><p>On Stocktwits, retail sentiment for Novartis was ‘bearish’ amid ‘low’ message volume.</p><figure class="image"><img style="aspect-ratio:972/144;" src="https://news.stocktwits-cdn.com/nvs_ss_png_06890b22a7.webp" alt="nvs ss.png" width="972" height="144"><figcaption>NVS sentiment and message volume as of November 21 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/NVS">Novartis’ stock</a> has declined 0.6% so far in 2025.</p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs

Novartis raised peak sales targets for Kisqali and Scemblix, adding to its roster of multi-billion-dollar oncology drugs.

Equity

Avantax Advisory Services Inc. Buys 2,878 Shares of Novartis AG $NVS

Avantax Advisory Services Inc. lifted its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 8.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC...

<ul class="summary-bullets"><li>Layoff filings show UnitedHealth’s Optum units planning the largest set of early-2026 job reductions among major healthcare employers.</li><li>Merck, Bristol Myers Squibb, and Novartis are pushing through additional cuts as part of restructuring and cost-saving programs.</li><li>The reductions come as companies confront pressures ranging from patent cliffs and pipeline reshuffling to operational overhauls and profitability targets.</li></ul><p>A new wave of layoffs continues to sweep&nbsp;the country, this time across the pharmaceutical and healthcare sectors, with Merck, Bristol Myers Squibb, Novartis, and multiple UnitedHealth Group Optum divisions filing advance notices of job cuts extending well into 2026.</p><p>The filings were submitted under the Worker Adjustment And Retraining Notification (WARN) Act&nbsp;in New Jersey, which requires employers to provide 60 days’ written notice before large-scale layoffs, giving workers time to prepare for unemployment and seek transition support.</p><h2 class="st-heading-2"><strong>Optum Layoffs Fit Into UnitedHealth Group’s Three-Year Reset</strong></h2><p>Several UnitedHealth Group units have filed WARN notices for early 2026, including Optum Care, which plans to cut 390 employees; Optum Services, with 49 reductions; and Optum Select Management, with 11 layoffs. The cuts come as UnitedHealth pushes through an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/united-health-charts-3-year-turnaround-plan-to-rebuild-margins-and-restore-swagger/cLPdSw7REPP">overhaul aimed at restoring profitability by 2027</a>, a plan that includes exiting unprofitable Medicare Advantage products, repricing coverage to reflect higher medical costs, and consolidating fragmented Optum systems.&nbsp;</p><p>The insurer expects to lose about one million Medicare Advantage members this year as part of the reset. Meanwhile, Optum Insight, still recovering from the Change Healthcare cyberattack, is rebuilding its technology footprint with thousands of new AI engineers and signing fresh enterprise clients.</p><h2 class="st-heading-2"><strong>Merck Cuts 204 Jobs As $3B Cost Program Accelerates</strong></h2><p>Merck will eliminate 204 roles at its Rahway campus between Feb.20 and May 11, 2026, extending the company’s broader $3 billion cost-cutting initiative announced in July. That program includes reducing roughly 6,000 positions, or about 8% of Merck’s workforce, as the company prepares for Keytruda’s 2028 patent expiration, which threatens a major revenue gap, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://endpoints.news/merck-will-shed-6000-jobs-as-it-eyes-3b-in-cost-cuts/">report</a> by Endpoints News.</p><p>Merck has attempted to reinforce its pipeline with acquisitions such as Verona Pharma and prior deals involving Prometheus Biosciences and China licensing agreements, even as it re-trains staff to fill roles in growth areas.</p><h2 class="st-heading-2"><strong>Bristol Myers Squibb Nears 1,000 Local Job Cuts</strong></h2><p>Bristol Myers Squibb is preparing to cut 110 jobs at its Lawrence Township campus between Feb. 12 and March 13, 2026, the latest in a steady stream of layoffs across the site. The location has already absorbed several rounds of cuts, including 516 positions announced in May, 290 earlier in the year, 68 in June, and 282 in September. That comes on top of more than 1,000 layoffs statewide last year.</p><p>The reductions are part of a sweeping restructuring effort Bristol Myers Squibb began in 2024, aimed at saving $1.5 billion by the end of 2025. The company has since doubled down, outlining plans to remove another $2 billion in costs by 2027 through organizational simplification, site consolidation, efficiency improvements, and the winding down of about a dozen R&amp;D programs.</p><h2 class="st-heading-2"><strong>Novartis Plans 60 Layoffs&nbsp;</strong></h2><p>Novartis plans to lay off 60 employees at its East Hanover headquarters by June 2026, adding to a series of workforce changes the company has made over the past few years. The cut follows a much larger 426-person reduction announced earlier this year, which stemmed from a reshuffling of the company’s cardiovascular commercial operations as Entresto approaches its loss of exclusivity.</p><p>The cuts are the latest in a series of changes at the site. In 2024, Novartis also cut 139 positions from sales teams working on Xolair, Tafinlar, and Mekinist. In 2022, it restructured the company by merging its oncology and pharmaceuticals units. The company has also been trying to reduce its operational costs and increase profitability, targeting a core operating margin of over 40% by 2027.</p><h2 class="st-heading-2"><strong>Merck Draws Bullish Mood On Stocktwits</strong></h2><p>On Stocktwits, Merck stood out with ‘bullish’ sentiment amid ‘high’ message volume, while Novartis, Bristol Myers Squibb, and UnitedHealth Group all saw ‘bearish’ sentiment, with the first two on ‘low’ volume and UnitedHealth on ‘normal’ volume.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Merck (MRK), Bristol Myers Squibb (BMY), Novartis (NVS), and multiple UnitedHealth Group (UNH) Optum divisions filed advance notices of job cuts extending well into 2026. (Photo credit: Getty Images)

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices

Layoff filings show UnitedHealth’s Optum units planning the largest set of early-2026 job reductions among major healthcare employers.

Novartis To Build Flagship Manufacturing Hub In North Carolina

(RTTNews) - Novartis (NVS) announced plans to expand its operations in North Carolina with the creation of a new flagship manufacturing hub featuring end-to-end capabilities. This strategic...

Novartis AG $NVS Shares Acquired by Cetera Investment Advisers

Cetera Investment Advisers lifted its position in Novartis AG (NYSE:NVS - Free Report) by 16.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and...

Financial Gravity Companies Inc. Makes New $5.35 Million Investment in Novartis AG $NVS

Financial Gravity Companies Inc. purchased a new position in shares of Novartis AG (NYSE:NVS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with...

Creative Planning Purchases 11,267 Shares of Novartis AG $NVS

Creative Planning increased its position in Novartis AG (NYSE:NVS - Free Report) by 2.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 398,258...

Woodley Farra Manion Portfolio Management Inc. Grows Stake in Novartis AG $NVS

Woodley Farra Manion Portfolio Management Inc. grew its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing...

Novartis AG $NVS Shares Acquired by ProVise Management Group LLC

ProVise Management Group LLC increased its holdings in Novartis AG (NYSE:NVS - Free Report) by 2.7% during the second quarter, according to its most recent filing with the Securities and Exchange...

Fiera Capital Corp Buys Shares of 43,671 Novartis AG $NVS

Fiera Capital Corp purchased a new position in Novartis AG (NYSE:NVS - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange...

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

NVS
Novartis AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVS News

NVSNovartis AG